Article Text

FRI0315 A Prospective Study To Assess Responsiveness of Clinical and Ultrasound Outcome Measures for Musculoskeletal Sle
  1. A.S. Zayat1,2,
  2. K. Mahmoud1,2,
  3. M.Y. Md Yusof1,2,
  4. H. Cassamoali1,2,
  5. M. D'Agostino1,2,
  6. P. Emery1,2,
  7. E.M. Vital1,2
  1. 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds
  2. 2NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom


Background Musculoskeletal manifestations affect up to 95% of SLE patients. Assessment can be problematic as not all patients have swelling. There is a clinical need to better select SLE patients with musculoskeletal symptoms who may respond to therapy and assess their response. We previously analysed 100 patients with MSK symptoms and showed that ultrasound (US) detects synovitis in patients with no clinical swelling.

Objectives To assess the responsiveness of clinical assessment tools and US in musculoskeletal SLE.

Methods 107 patients fulfilling ACR/SLICC criteria for SLE with musculoskeletal involvement were analysed in a cross-sectional study. 16 of these with current inflammatory symptoms entered a pilot study of US before and after intramuscular injection of depomedrone 120mg. These 16 patients were followed up and assessed clinically using BILAG, SLEDAI, patient VAS, physician VAS, tender joint count, swollen joint count) and US of hand (joints and tendon sheath) at 0, 2 and 4 weeks.

Results Of 107 patients only 35 (32.7%) had swelling clinically at baseline but 53 (49.5%) had US synovitis. Response in US and clinical parameters for the 16 longitudinal patients is shown in Table1.

Table 1

Conclusions Although swollen joint count was responsive to change with therapy, US was more sensitive in detecting active joints disease at baseline and showed greater and more significant change with therapy. The responsiveness of swollen joints likely explains the responsiveness in BILAG musculoskeletal system index and physician VAS. However, tender and symptomatic joint counts, as well as SLEDAI, were poorly responsive to therapy. Overall, US is the tool most responsive to change for monitoring musculoskeletal disease activity in SLE.

Disclosure of Interest None declared

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.